BAC and GE Healthcare Collaboration Wins Industry Award
News Oct 11, 2012
BAC BV has announced that a successful long-term collaboration with GE Healthcare, the healthcare business of GE, to develop innovative purification media for the production of novel types of biopharmaceuticals has been recognized with the “Collaboration of the Decade Award -Downstream Processing” at the BioProcess International Awards 2012.
Since 2006, BAC and GE Healthcare have worked closely together, developing products aimed at improving the efficiency of biopharmaceutical manufacturing.
With a focus on the development of affinity resins for highly efficient purification, the collaboration has led to the commercial launch of seven products which are now used worldwide in the manufacture of potentially life-saving medicines such as coagulation factors, various antibody formats, biosimilars and gene-therapy vectors.
Worldwide demand for biopharmaceuticals is set to increase, driven by an ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases.
Laurens Sierkstra, CEO of BAC, said: “We are delighted to see our joint efforts to enable the development of the latest biotherapeutics recognized by those in the industry. Our on-going collaboration with GE Healthcare has been highly productive and responsive to the needs of end-users.”
Commenting on the award, Dr. Nigel Darby, Vice President of BioTechnologies, GE Healthcare Life Sciences added, “Collaborations between companies with complementary technologies and expertise are vital in making the advances that will help us tackle global challenges such as the increasing burden of disease and cost of healthcare. With global demand for cost effective biotherapeutics set to rise, collaborations like ours that deliver innovative supporting technologies will play an increasingly significant role.”
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018